No full text
Article (Scientific journals)
"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
Brusselle, G.; Michils, A.; Louis, Renaud et al.
2009In Respiratory Medicine, 103 (11), p. 1633-42
Peer Reviewed verified by ORBi
 

Files


Full Text
No document available.
Full Text Parts
‘Real-life’ effectiveness of omalizumab in patients with severe persistent asthma..._Brusselle_09_RespirMed.pdf
Publisher postprint (372.14 kB)
Request a copy
_Real-life_ effectiveness of omalizumab in patients with severe persistent asthma..._Brusselle_09_RespirMed.do.pdf
Author postprint (310.88 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] OBJECTIVE: To evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in Belgium. METHODS: Effectiveness outcomes included improvement in 2005 global initiative for asthma (GINA) classification, physician-rated global evaluation of treatment effectiveness (GETE), quality of life (Juniper asthma-related quality of life (AQLQ) and European quality of life questionnaire 5 dimensions (EQ-5D)), and severe asthma exacerbations. Patients studied included both intent-to-treat and per-protocol populations. RESULTS: The sample (n=158) had a mean age of 48.17+/-17.18 years, and a slight majority were female (53.8%). Despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists, all patients experienced frequent symptoms and had exacerbations in the past year. At 16 weeks, >82% had good/excellent GETE (P values <0.001), >82% had an improvement in total AQLQ scores of > or =0.5 points (P<0.001), and >91% were severe exacerbation-free (P<0.001). At 52 weeks, >72% had a good/excellent GETE rating (P<0.001), >84% had improvements in total AQLQ score of > or =0.5 points (P<0.001), >56% had minimally important improvements in EQ-5D utility scores (P=0.012), and >65% were severe exacerbation-free (P<0.001). Significant reductions in healthcare utilization compared to the one year prior to treatment were noted. CONCLUSION: The PERSIST study shows better physician-rated effectiveness, greater improvements in quality of life, greater reductions in exacerbation rates, and greater reductions in healthcare utilization than previously reported in efficacy studies. Under real-life conditions, omalizumab is effective as add-on therapy in the treatment of patients with persistent severe allergic asthma.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Brusselle, G.
Michils, A.
Louis, Renaud ;  Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
Dupont, Liliane ;  Université de Liège - ULiège > Interface Entreprises-Université
Van de Maele, B.
Delobbe, A.
Pilette, C.
Lee, C. S.
Gurdain, S.
Vancayzeele, S.
Lecompte, P.
Hermans, C.
MacDonald, K.
Song, M.
Abraham, I.
More authors (5 more) Less
Language :
English
Title :
"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
Publication date :
2009
Journal title :
Respiratory Medicine
ISSN :
0954-6111
eISSN :
1532-3064
Publisher :
Elsevier, Oxford, United Kingdom
Volume :
103
Issue :
11
Pages :
1633-42
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 21 January 2010

Statistics


Number of views
165 (7 by ULiège)
Number of downloads
409 (2 by ULiège)

Scopus citations®
 
184
Scopus citations®
without self-citations
172
OpenCitations
 
143

Bibliography


Similar publications



Contact ORBi